ArticleResearch square2026
The Impact of CYP3A5 Genotype on Tacrolimus Pharmacokinetics in Children following Heart Transplant.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tacrolimus is a first-line immunosuppressant used after solid organ transplantation that suffers from extensive intra- and inter-patient variability and a narrow therapeutic window. Tacrolimus clearance is predominantly mediated by CYP3A4 and CYP3A5, with evidence indicating that pharmacogenetic (PG) differences in these enzymes drive significant changes in tacrolimus pharmacokinetics (PK) and therapeutic tacrolimus dosing. The current study investigates the hypothesis that CYP3A4/5 genetic variation alters tacrolimus dose requirement and metabolite concentration in children following pediatric heart transplant. Saliva and whole blood samples were collected from children who previously received a heart transplant as part of a tacrolimus PG/PK study. A total of 64 children were included in the analysis, which found that children carrying a CYP3A5*1 allele required a 2.7-fold higher tacrolimus dose (p<0.0001) than individuals with the CYP3A5*3/*3 genotype. Dose-normalized tacrolimus and metabolite concentrations were significantly lower in children with the CYP3A5*1 allele. Combined, these data support the impact of CYP3A5 genotype on tacrolimus PK and demonstrate the need for larger studies to confirm the clinical importance of this genotype for appropriate tacrolimus dosing in pediatric heart transplant recipients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.